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THE EFFECTS OF ACUTE NICOTINE ABSTINENCE ON VIGILANCE AND VERBAL
MEMORY IN NON-DIAGNOSED SMOKERS

David W . Ayer, Ph.D.
Western Michigan University, 2007

Research has shown a differential prevalence of smoking in the schizophrenic
population compared to other psychiatric and non-diagnosed populations. The three
most commonly investigated reasons for this differential prevalence in schizophrenics
are: the self-medication hypothesis, side effects hypothesis, and sociological hypothesis.
The self-medication hypothesis which proposes that schizophrenics smoke at a higher
rate to ameliorate cognitive deficits is the most substantiated by the research. O f current
interest is the possible role of nicotine in improving performance on vigilance and verbal
memory, the two areas shown to be most related to impaired social functioning in
schizophrenics. It is difficult to make comparisons among the existing research
investigating the effects of nicotine on verbal memory and vigilance in non-diagnosed
populations due to the use of differing nicotine delivery mechanisms, populations, and
assessment tools. The current study implemented standardized and psychometrically
sound assessments of verbal memory (immediate and delayed) and vigilance to assess
in smokers the impact of nicotine via the participants’ normal smoking behaviors.
Following acute abstinence (> 6 hrs) 15 non-diagnosed smokers completed the Conner’s
Continuous Performance Test (CPT) and Rey Auditory Learning Test (RVLT) using a
counterbalanced design. Results of the repeated measures analysis revealed no
statistically significant effect of nicotine. Subsequent covariate analysis revealed a
significant effect of nicotine on RVLT total score when controlling for sex and number of
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cigarettes per day. Likewise covariate analysis revealed a significant effect of nicotine
on the CPT overall index and hit rate block change sub-measures when controlling for
age.

An examination of trend lines revealed a consistent decrease in performance on

all CPT sub-measures and on RVLT measures related to memory storage as a result of
nicotine abstinence, while nicotine abstinence improved performance on RVLT
measures of memory storage. While it is difficult to draw conclusions from the current
study, a less robust finding in a non-diagnosed population than is typically found in
diagnosed populations might be suggestive of different reasons for smoking between the
populations.
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1

C HA PTER I

INTRO DUC TIO N

Research has shown a differential prevalence of smoking in the schizophrenic
population compared to both other psychiatric and normal populations. A study
conducted by Hughes, Hatsukami, Mitchell, and Dahlgren (1986) was the first controlled
study to show higher prevalence of smoking in individuals diagnosed with schizophrenia.
In this study, the researchers compared the prevalence of smoking in 277 psychiatric
outpatients to the prevalence of smoking in samples of 1440 and 17,000 local and
national normal populations, respectively.

The authors found that 88% of the

schizophrenic population smoked compared to 52% of other psychiatric disorders, 30%
of the local population, and 33% of the national population.
Since the Hughes et al study (1986), several other studies have also shown
differential prevalence of smoking when comparing the schizophrenic population (7090% ) to other psychiatric populations (30-54% ) and to the general population (28-35% )
(Diwan, Castine, Pomerleau, Meader-Woodruff, & Dalack 1998; Glassman, 1993; Goff,
Henderson, & Amico, 1992; Lohr & Flynn, 1992). Attempts to explain this phenomenon
followed from these findings.

Hypotheses for Differential Prevalence

Sociological hypothesis
It is commonly held that environmental and sociological factors are involved in
substance abuse of any form (Poling & Byrne (Eds.), 2000). Lohr and Flynn (1992)
suggested that sociological factors such as institutionalism, low SES, or boredom may
contribute to the high rates of smoking in schizophrenia. Several researchers have
examined the possible role these factors may play in the etiology and maintenance of
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smoking in schizophrenics. The Hughes et al (1986) study found that even when
controlling for age, sex, marital status, socioeconomic status, alcohol use, caffeine use,
or institutionalization of the psychiatric patients, higher prevalence of smoking was still
shown to exist for schizophrenic patients. A study conducted by de Leon et al. (1995)
also suggested that neither institutionalization nor “boredom” contributed to the increase
in smoking for schizophrenics. A replication of this study confirmed these findings (de
leon, Tracy, McCann, McGrory, & Diaz, 2002). Strassnig, Brar, & Ganguli (2006) found
high rates of smoking in schizophrenics to be unrelated to income, body mass intake
(BMI), fat or caloric intake. A Finnish study reported the only sociological factor that
correlated with smoking in schizophrenic patients was their father’s smoking status
(Riala, Hakko, Isohanni, Puota, & Rasanen, 2005)
Other sociological factors proposed to explain the high rate of smoking in
schizophrenics include the lack of availability of alternative reinforcers (smoking may
represent the schizophrenics only opportunity for socialization) and that isolation from
mainstream society may shield them from anti-smoking information (Lyon, 1999;
Ziedonis, Kosten, Glazer, & Frances, 1994). A study conducted by Spring, Pingitore,
and McChargue (2003) indicate these may not be valid explanations. These authors
found schizophrenics to be just as aware of the pros and cons of smoking as the
sampled non-psychiatric population. Schizophrenic subjects indicated that the pros
outweighed the cons while the comparison group viewed the pros and cons as about
equal. The authors also reported that when schizophrenics were asked to rate the
reinforcing value of smoking compared to a variety of other items and behaviors likely to
be considered reinforcing, they chose smoking at a two to one rate over the comparison
group. Of interest, the authors found that both schizophrenic and depressed heavy
smokers attributed greater reward value to smoking than did the non-psychiatric
comparison group.

It may be that cigarette smoking is one of the few reinforcers able to
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overcome reward circuitry abnormalities. This will be explored in more detail when we
turn our discussion to neurotransmitters and schizophrenia later in the paper.
In summary, although sociological factors have been proposed, to date they have not
been demonstrated to account for the high rates of smoking among schizophrenics.

Side effects hypothesis
Another frequently given hypothesis for the higher prevalence of smoking in
schizophrenics is its role in the possible amelioration of medication side effects. Several
studies have shown nicotine to reduce the prevalence and severity of neurolepticinduced parkinsonism in schizophrenic patients (Decina, et al., 1990; Goff et al., 1992;
Sandyk, 1993; Ziedonis et al., 1994). Investigations into nicotine’s effect on other
movement disorders such as akathisia (Goff et al., 1992; Barnes et al., 2006) and tardive
dyskinesia have produced mixed results (Goff et al., 1992; Ziedonis et al., 1994).
A related issue concerns which of two types of medication a schizophrenic is taking,
typical or atypical (sometimes referred to as novel) anitpsychotics. The current body of
evidence suggests that typical anitpsychotics may increase smoking rates while
atypicals decrease smoking rates (George, Ziedonis, et al. 2000; Green, A. I., 1999;
McEvoy, Freudenreich, Levin, & Rose, 1995; Barnes et al., 2006) in schizophrenics.
However, one study showed that high doses of typical anitpsychotics did not increase
the rate of smoking in schizophrenics, but did increase the rate of smoking in non
schizophrenics (de Leon et al., 1995). Additionally de Leon et al. (1995) reported
smoking to be higher in the schizophrenic population independent of type of neuroleptic
received, or dose of antipsychotic (de Leon et al., 2002). A review of the literature
reveals that psychiatrists prescribe higher doses of neuroleptics in patients who smoke
than in those who do not smoke (Ziedonis et al., 1994; de Leon et al., 1995; de Leon et
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al., 2 0 0 2 ). So as de Leon and colleagues suggest (2002), smoking to reduce
medication side effects appears to be a flawed strategy.
A more serious threat to this hypothesis is the fact that a high rate of substance
abuse (Green, A. I., 1999), and specifically nicotine dependence which has been shown
to exist independent of general substance abuse in this population (de Leon et al., 1995;
de Leon et al., 2002), exists in schizophrenic patients prior to the receipt of any
pharmacological treatments.

McEvoy and Brown (1999) reported that unmedicated,

first-episode patients smoked at the same rate as chronic schizophrenic patients.
Barnes, Mutsatsa, Hutton, Watt, and Joyce (2006) also found a high rate of smoking in
first episodes schizophrenic patients. Some authors have suggested that smoking in
adolescence and early adulthood may be predictive of later development of
schizophrenia, and may be evidence of a prodromal phase of schizophrenia. A study of
male Israeli military recruits revealed that smokers were at greater risk for later
development of schizophrenia, and that number of cigarettes smoked was significantly
associated with risk for schizophrenia (Weiser et al., 2004). A Finish study reported that
initiation of smoking was temporally related to the onset of schizophrenia suggesting that
smoking may be an indicator of the prodromal phase of schizophrenia (Riala et al.,
2005). Another study using the same cohort found that individuals who would later
develop schizophrenia and who smoked showed poorer school performance overall;
specifically in physics, mathematics, reading, and music (Riala, Hakko, Isohanni,
Jokelainen, et al., 2005). An interesting study conducted by Zammit et al. (2003)
suggests that initiation of smoking at an earlier age (18 - 25) may be a sign of the
prodromal phase of schizophrenia, while smoking after this age may offer a protective
effect against the development of schizophrenia.
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In sum, while medication side effects may or may not contribute to the maintenance
of smoking in schizophrenics, it is clear that they are not responsible for the etiology of
the disproportionately high rates of smoking in schizophrenics.

Self-medication hypothesis
Another commonly referenced explanation for the high rate of smoking in the
schizophrenic population is that it is an attempt to ameliorate schizophrenic
symptomology and/or cognitive deficits. It is widely held that neurotransmitter
abnormalities are responsible for the positive and negative (pathological) symptoms of
schizophrenia as well as the cognitive deficits that accompany the disorder. It is
proposed that nicotine may ameliorate some of these abnormalities and, in effect,
normalize certain schizophrenic symptoms (Lyon, 1999). In the “Schizophrenia,
neurotransmitters, cognition and nicotine” section of this paper specific neurotransmitters
associated with pathological and cognitive deficits in schizophrenia are discussed. In
the current section we will focus on studies regarding the effects of nicotine on positive
and negative symptoms, and then review the large body of evidence regarding nicotine
effects on cognition; specifically those deficits seen in schizophrenia.
Research conducted to investigate nicotine’s role in improving the pathological
symptoms of schizophrenia has produced mixed findings (Goff et al., 1992; Smith,
Singh, Infante, Khandat, & Kloos, 2002; Ziedonis et al., 1994). The Ziedonis et al.
(1994) study demonstrated an increase in positive symptoms for schizophrenic patients
who smoked compared to patients who did not smoke and no difference in negative
symptoms between the two groups, except for very heavy smokers who showed a
decrease in negative symptoms. The Goff et al. (1992) study showed more of both
negative and positive symptoms in schizophrenic smokers. As discussed by Zeidonis et
al. (1994), these studies were observational in design which allows for discussion about
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association but not causation. Dalack and Meador-Woodruff (1996) conducted a review
of the existing literature regarding the relationship between smoking and schizophrenic
symptomology and concluded there had been no studies to date that examined this
relationship via experimentally controlled manipulation of smoking behavior. These
same investigators (Dalack, Becks, Hill, Pomerleau, & Meador-Woodruff, 1999)
conducted a study involving 12 patients with the diagnosis of schizophrenia and all
active smokers undergoing 3 days of smoking abstinence randomly assigned to either
an active or placebo nicotine patch, followed by one day of ad libitum smoking and then
a return to the 3 day abstinence condition wherein patients where assigned to the active
or placebo patch condition opposite of what they received during the first abstinence
session (i.e. crossover design). There were no significant changes in either positive or
negative symptoms in relation to patch status (active or placebo). A review of the
literature regarding smoking cessation in psychiatric patients conducted by Haustein,
Haffner, and Woodcock (2002) led these authors to conclude that smoking abstinence,
even if it leads to withdrawal symptoms, has no negative impact on psychiatric
symptoms.

A study by Smith, Singh, Infante, Khandat, and Kloss (2002) revealed a

significant decrease in negative symptoms and no change in positive symptoms.

It may

be that any positive impact seen on negative symptoms is due to the small correlation
between negative symptoms and cognitive deficits, or due to the use of measures of
negative symptoms that fail to distinguish these from cognitive deficits.
Irrespective of conclusive evidence for nicotine’s effect on negative or positive
symptoms of schizophrenia, as discussed in the previous section, it is commonly found
that the initiation of smoking, and other substance abuse, occurs prior to the emergence
of obvious positive or negative symptomology. This raises serious doubt about the
legitimacy of the hypothesis for differential prevalence due to self-medicating traditional
schizophrenic symptoms.
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Research investigating the role of nicotine in ameliorating cognitive and attentional
deficits is more promising. Studies have shown rates of cognitive impairment in
schizophrenics to be as high as 85% (Palmer, Heaton, Paulsen, Kuck, Braff, et al.,
1997). Although the positive symptoms of schizophrenia (e.g. delusions and
hallucinations) have historically garnered most of the attention, more recently cognitive
deficits have gained prominence as the core psychiatric feature of schizophrenia (Green,
1999; Meltzer, 1999b; Palmer, et al., 1997). Both Green (1999) and Meltzer (1999b)
point out that cognitive deficits in patients who later develop schizophrenia are present
during their childhood before any positive or negative symptoms are present. In fact,
some researchers view certain cognitive deficits as markers for the onset of
schizophrenic symptomology (Green & Nuechterlein, 1999; Park, Puschel, Sauter,
Rentsch, & Hell, 1999). Further many cognitive deficits persist long after the positive
symptoms of schizophrenia remit (Green, 1999).
Cognitive deficits are also being seen as distinct from schizophrenic symptomology.
Several lines of evidence, in addition to those listed in the preceding paragraph, give
support for this view. Traditional pharmacological treatment with typical neuroleptics,
while at least moderately effective at treating the symptomology of schizophrenia, fail to
not only improve the cognitive deficits, but frequently result in further cognitive
impairment (Meltzer, 1999b). Research also shows certain cognitive deficits to be
present in the first-degree asymptomatic relatives of schizophrenics (Park, Knopick,
McGurk, & Meltzer, 1995; Park, et al., 1999). In a review of the relevant research,
Green and Nuechterlien (1999) state that cognitive deficits and positive symptoms show
almost no relationship, and while the relationship between negative symptoms and
cognitive deficits is a little stronger, the percent of variance explained is still only 1015%.
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The literature investigating the effect of nicotine on cognition is sizeable and thus
warrants separate discussion. The evidence put forth in this next section clearly shows
that the mitigation of cognitive deficits hypothesis currently garners the most empirical
support for the explaining the greater prevalence of smoking among the schizophrenic
population.

Nicotine and Cognition
This section will focus on the recent (£ 20yrs) literature demonstrating a relationship
between nicotine and certain cognitive constructs. This begins with a discussion of
nicotine’s influence on two categories of cognition in the normal population: learning and
memory, and attention and vigilance, followed by a discussion of the relationship
between nicotine and cognition in the schizophrenic population and any differential
effects of nicotine on cognition between the normal and schizophrenic populations. This
section closes with a discussion of psychophysiology, neurotransmitters, and nicotine as
they relate to important cognitive deficits seen in schizophrenia.

Non-diagnosed
Learning and memory
Mangan (1983) investigated the effects of .7mg and 1.3 mg yield cigarettes in normal
smokers on acquisition and retention of verbal material. In the first measure, pairedassociate learning, subjects were required to learn a 10-pair set of words, broken into
high-interference (HI) and low-interference (LI) pairs, until they could produce two
successive error-free reproductions of the 10-pair set. HI pairs consisted of highly
associated words such as miss/take or black/white and the individual words were
redistributed in pairs that would maximize interference, e.g. miss/white or black/take. LI
pairs were words that were not associated in common usage.

Acquisition was broken
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into three separate sessions where prior to acquisition subjects chatted with the
experimenter for 5 minutes in the first session, smoked a 1.3mg yield cigarette in the
second, and smoked a ,7mg cigarette in the third session. Subsequent to each of these
sessions the subjects were asked to sit quietly for 30 minutes and then to recall the 10pair sets. For the second measure, subjects were required to participate in a serial
learning task where they were asked to learn 12 sets of 20 words presented at the rate
of one word every three seconds; immediately following the trial they were asked to
recall as many words as possible. As with the paired-associate task acquisition
occurred in three separate sessions under the same conditions. Results indicated that
smoking either yield cigarette improved retention under both HI and LI conditions while
the 1.3 mg dose impeded acquisition under the LI condition and improved acquisition
under the HI condition (.7mg dose had no effect on acquisition under either condition).
For the serial learning measure both doses improved primacy responses, indicating that
the words seen first in the acquisition trials were more frequently recalled.
Similarly, two other studies demonstrated that ingesting nicotine via controlled
smoking or nicotine tablet (Peeke & Peeke, 1984; Warburton, Wesnes, Shergold, &
James, 1986) prior to acquisition of verbal material facilitated recall of that material.
These studies led researchers to question whether nicotine was exerting its influence on
recall by an attentional mechanism at the time of acquisition or if it was directly affecting
memory storage. Warburton, Rusted, and Fowler (1992) conducted a study designed to
answer this question. This study involved normal addicted smokers who had abstained
from smoking for at least 10 hrs prior to participating in two experimental conditions.
There were two sessions within each experimental condition; low nicotine cigarette
(0.6mg) and denicotinised cigarette (<0.1 mg) sessions. Subjects were randomly
assigned to cigarette type, order of session, and word list. In experiment 1 subjects
were given a four-word group for 4s, they then took a puff off a cigarette and rehearsed
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the words for 10s. Subjects repeated this procedure for 8 four-word groups.
Immediately upon completion of the 8th four-word group, subjects were required to write
down as many words as possible from all four-word groups. Experiment 2 involved the
same procedures except subjects were asked to recall the four-word groups 10 minutes
after the last four-word group. Subjects were required to engage in a task during those
10 minutes to prevent rehearsal. The results showed that nicotine improved immediate
recall of the words towards the end of the four-word lists (suggesting an attentional
mechanism) and improved delayed recall of words towards the beginning of the fourword lists (suggesting a direct effect on memory storage). Since nicotine was ingested
after exposure to the four-word lists the authors suggest that nicotine has a direct effect
on memory storage in addition to its attentional effects. More recently, researchers have
suggested that nicotine effects on storage may be a result of its attentional effects
(Poltavski & Petros, 2005; Newhouse, Potter, & Singh, 2004). Newhouse and
colleagues (2004) point out that increased attention on the “front end” would be
beneficial for acquisition, storage and retrieval.
Some studies have shown nicotine to exert negative or no influence on memory, and
others have shown dose-dependent and task difficulty-dependent effects as were
reported in the Mangan (1983) study. Herzig, Callaway, Halliday, Naylor, and Benowitz
(1998) administered 3 doses of cotinine, the active metabolite of nicotine, to nonsmokers and observed a dose-dependent deleterious effect of nicotine on word list
recall, i.e the higher the dose of continine administered the fewer the number of words
participants could remember.

Kleykamp, Jennings, Blank, and Eissenberg (2005)

found 2 or 4 mg nicotine gum administered to never smokers had no effect on a working
memory task. Poltavski and Petros (2005) investigated the impact of nicotine delivered
via a transdermal patch (21 mg for smokers, 7 mg for non-smokers) vs placebo in
smokers and non-smokers on prose recall. These investigators found smokers given
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the active patch recalled less prose material than smokers given the placebo patch,
while non-smokers who were given the active patch performed better on the prose recall
task. These authors suggest the 21 mg patch given to predominantly light smokers
resulted in too much nicotine for them causing a decrement in performance, while the 7
mg patch given to non-smokers was just enough to optimize performance.

The authors

point to inconclusive findings in the literature regarding the effect of nicotine on learning
and memory as being suggestive of a dose-dependent effect. Later in this section we
will see further evidence for a dose dependent, and in fact a Yerkes-Dodson or invertedU effect of nicotine in normals.
In the previous paragraphs we reviewed the literature on the acute effects of nicotine
on learning and memory and found different effects related to nicotine dose, smoking
status (smoker vs nonsmoker), construct measured, task difficulty, and the suggestion
that nicotine may optimize rather than linearly increase performance on certain
constructs. Studies examining the effects of chronic nicotine use reveal a clearly
detrimental effect of long-term nicotine use on cognition. For example, Hill, Nilsson,
Nyberg, and Blackman (2003) assessed a large cohort (>600) of individuals aged 35 80 and found continuous smokers performed significantly worse than non smokers on
cognitively demanding tasks such as block design and free recall of unrelated word lists.
Further, they found a significant negative correlation between the number of years and
cigarettes smoked and performance on these tasks. Likewise Deary, Pattie, Taylor,
Whiteman, Starr, and Whalley (2003) reported chronic nicotine use decreased overall IQ
over time, and Razani, Boone, Lesser, and Weiss (2004) showed heavy smoking history
to have a negative impact on executive functioning. Of interest in the current study, Paul
et al. (2006) showed older smokers performed worse on delayed recall tasks than either
older nonsmokers or younger smokers.
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Although it might be thought that cognitive decline in older smokers is due to
smoking related illness such as cardiovascular disease, the current research suggests
otherwise. In the Hill et al. (2003) study, the investigators screened, by design, to
include only healthy adults and further showed no difference in self-reported health
between older smokers and nonsmokers making differences due to cardiovascular or
other health factors unlikely. Likewise in the Paul et al. (2006) study the investigators
screened for any mental or physical condition that may impact cognition (e.g. cardiac
disease, hypertension, diabetes, drug and alcohol addiction) and still found older adult
smokers to have poorer delayed recall. Razani et al. (2004) included vascular illness
status as a covariate in their analysis and found it unrelated to cognitive decline in older
smokers. Deary et al. (2003) could not state whether or not the health status of their
sample contributed to the observed effect but did comment that previous studies had
failed to show the effect on cognitive decline in older smokers was due to cardiovascular
disease. Further, Stewart, Deary, Fowkes, and Price (2005) collected ankle brachial
pressure (measure of atherosclerosis) on 2,000 men and women over the age of 50 and
found degree of atherosclerosis to be independent of and smoking-related cognitive
decline in that population. Brody et al. (2004) utilized MRI to study the brains of smokers
and non smokers and found smokers had smaller gray matter volumes and lower gray
matter densities than nonsmokers in the prefrontal cortex (PFC) bilaterally, along with
smaller volumes in the left dorsal anterior cingulated cortex (ACC) and lower gray matter
densities in the right cerebellum. This suggests direct effects, rather than secondary
health effects, on cognition in chronic older smokers.
Attention and vigilance
In a study designed to examine the effects of varying levels of nicotine (via smoking)
deprivation on several cognitive tasks (Hatsukami, Fletcher, Morgan, Keenan, & Amble,
1989), these researchers found 24 hr deprivation to result in slower reaction time (RT),
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greater variability in RT, and an increase in errors of commission on a vigilance task
(Yellin, 1980). On the Trail Making Test (B), Hatsukami et al. (1989) found significant
effects on cognitive performance after 4 hrs of deprivation. In a more experimentally
rigorous and counterbalanced study, Pritchard et al. (1992) investigated non-deprived
smokers’ performance on the Conner’s Continuous Performance Task (CPT) in one
session after having smoked a 0.6 mg nicotine cigarette immediately prior to the task,
and in another session after having not smoked for 20-min. These researchers
assessed the effects on RT and errors of commission and found an improvement in RT
with no corresponding increase in errors of commission in the smoking sessions. They
also found no interaction effect between order of session and smoking condition,
indicating no practice effects. Koelega (1993) reviewed 17 studies that examined the
effect of nicotine on various vigilance tasks and found a significant overall effect in 11 of
these, with two additional studies showing an effect on performance with low dose
nicotine only. Koelega noted that those studies that failed to find an effect, failed to use
a cross-over or counterbalanced design.
Several other studies have examined the effects of nicotine delivered via patch in
both non-smoking and smoking populations. Levin, Conners, Silva, Hinton, Meek, et al.
(1998)

examined the effect of a 7 mg nicotine patch on CPT performance in non-

smokers. In a counterbalanced design the researchers tested subjects on the CPT 3hr
and 10-min after either receiving a 7 mg nicotine patch or a placebo patch. Subjects
were tested again under the alternate treatment condition (active/placebo,
placebo/active) at least four days following the initial testing session and condition. The
results showed a decrease in errors of omission, decrease in RT variability and an
increase in the overall composite measure of attention (higher scores indicate increased
attention) for the nicotine patch group. As with the Pritchard et al. (1992) study, there
was no corresponding increase in errors of commission nor were there any order or
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practice effects. Another study conducted by Mancuso, Andres, Ansseau, & Tirelli
(1999) also revealed 21 mg nicotine patch to increase performance on the Rapid Visual
Information Processing (RVIP) test of vigilance in smokers deprived for 10hrs. In a
review of studies involving subcutaneous (SC) administration of nicotine, Heishman
(1998) found that nicotine administered SC also increased rate and accuracy scores on
the RVIP in both abstinent smokers and in nonsmokers.
Although performance enhancing effects of nicotine on vigilance are the most widely
and consistently reported, not all studies have found this effect. Poltavski and Petros
(2005) randomized smokers and non-smokers to either active (21 mg for smokers, and 7
mg for non-smokers) or placebo transdermal patch and found that nicotine compared to
placebo did not enhance performance on the RVIP vigilance task in either the smoking
or non-smoking group. Kleykamp et al. (2005) also found no effect of placebo, 2 or 4 mg
nicotine gum administered in a randomized fashion to never smokers on attention
(alerting) nor on the other cognitive constructs that they measured. These authors noted
that studies on nicotine’s cognitive enhancing effects in never smokers have produced
mixed findings. Trimmel and Wittberger (2004) reported a 5 mg transdermal nicotine
patch administered to non-deprived smokers, deprived smokers, and never smokers
improved RT on a vigilance task while slowing RT on a visual search task in all groups,
showing that nicotine does not have a universal cognitive enhancement effect. These
authors also found that nicotine resulted in larger performance increase for females than
for males. Bekker, Bocker, Van Hunsel, van de Berg, and Kenemans (2005)
administered either 21 mg transdermal nicotine patch or placebo to 16 adult healthy
smokers to determine if nicotine has more of an effect on attention or response inhibition
using primarily the CPT. The authors reported the 21 mg transdermal nicotine patch
resulted in decreased (faster) RT and variability in response which they interpreted as an
increase in attention, but they also observed a decrease in the number of correct
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rejections indicating poorer response inhibition. As in the Trimmel and Wittberger (2004)
study, the nicotine patch in this study had both an enhancing and detrimental effect on
cognition depending upon the construct.
An interesting study by Poltavski and Petros (2006) points to differences among nonsmokers based on their baseline levels of attention. In this study the investigators
divided 62 male non-smokers into two groups, low attentiveness group and high
attentiveness groups, based upon their answers on a self-report survey. These groups
were then given either 7 mg transdermal nicotine or a placebo patch and administered
several cognitive assessments including the CPT, Wisconsin Card Sorting Test (W CST)
and the Stroop task 6 hours after application of the patch. The results revealed that the
low attention active patch group showed the greatest performance increase while
impaired W C S T performance was observed in the high attention active patch group.
While both the low and high attention nicotine groups committed fewer errors of
commission, showed increased d’ scores and fewer preservations on the C P T task;
between group comparisons revealed the low attention nicotine group showed the
greatest improvement on these measures.

As was referenced in regards to learning

and memory, these authors, and others, suggest that nicotine may optimize rather than
linearly improve performance.
Another question raised by researchers, since many studies have been conducted
with smokers who had abstained from smoking for some length of time, concerned
whether nicotine improved performance or simply relieved withdrawal-induced
performance deficits. This latter proposal is frequently referred to as the withdrawaldeficit hypothesis, and it is now widely refuted (Pritchard, Robinson, & Guy, 1992;
Koelega, 1993; and Pineda, Herrera, Kang, & Sandler, 1998). Pritchard et al. (1992)
point to numerous studies where nicotine was administered via tablet or gum to nonsmokers and was found to affect measures of memory and attention. Additionally these
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researchers point to several studies where nicotine administered to non-deprived
smokers produced an effect on reaction time and memory tasks. Their own study
(Pritchard et al., 1992) also showed nicotine delivered via controlled smoking to improve
vigilance in non-deprived smokers. More recently, Trimmel and Wittberger (2004)
showed transdermal nicotine patch to both increase and decrease RT on different tasks
independent of smoking status, i.e. non-deprived smokers, deprived smokers, and never
smokers. In a review of stimulant drugs and vigilance conducted by Koelega (1993), the
researcher concluded that nicotine’s effect on vigilance is not confined only to situations
where subjects were deprived of nicotine, nor only to situations involving long-tasks or
fatigued subjects. Koelega (1993) stated that nicotine’s effects were probably just easier
to detect in these situations.
In summary acute nicotine effects on attention and vigilance appear to be more
consistent than on learning and memory. Studies that were not consistent with the
larger body of evidence used a nicotine patch or nicotine gum as the delivery
mechanism. The review showed some differences in acute nicotine effects based on
construct measured, and also saw one study which reported sex differences. Harte and
Kanarek (2004) report that performance increases on measures of attention are most
consistently found in abstinent smokers. Koelega (1993) suggests that smoking status
may still be a relevant factor in determining the size of the effects of acute nicotine
abstinence on attention and vigilance. Many authors reviewed in this section discuss
small effect sizes in non-diagnosed populations. Kleykamp et al. (2005) suggest modest
effect sizes my be showing us that cognitive effects are not a significant factor for
initiation of smoking in this population. Issues regarding effect size and other variables
influencing nicotine effects on cognition and will be discussed in more detail later. For
now, acute nicotine effects in diagnosed populations, specifically, schizophrenia and
related disorders, will be reviewed.
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Schizophrenia and related cognitive disorders
In a review of the relevant literature, Kumari and Postma (2005) identify sensory
gating, eye movement abnormalities, and cognitive deficits as the most likely targets of
nicotine self medication in schizophrenia. These are of interest because schizophrenia
and related disorders display deficits in these areas, nicotine has been shown to impact
these areas, and differential effects of nicotine have been found between diagnosed and
non-diagnosed populations.
Sensory gating
Studies on sensory gating fall into two categories; pre-pulse inhibition (PPI) and
auditory gating (mostly of the P50 wave). PPI refers to the reduction of response to a
second strong stimulus if reliably preceded by a weaker stimulus. Similarly, auditory
gating is a decreased response to the second of two closely paired auditory stimuli
(typically measured by the P50 wave). PPI is considered a measure of sensorimotor
gating, while P50 response is considered a measure of sensory gating as it is measured
via EEG and does not involve a motor response. Schizophrenic patients have been
shown to display deficits in both PPI and the P50 response. A deficit in PPI (and P50
response) means the individual still displays an exaggerated response to the second,
strong stimulus despite the presence of the preceding weaker stimulus. Conversely
enhanced PPI (or P50 response) means diminishing the intensity of response to the
second, strong stimulus following exposure to the weaker stimulus. A diminished
response to the second, stronger stimuli would be the normal, or expected response.
Auditory gating, as measured by the P50 wave, has been shown to be diminished in
more than 85% of (Adler et al., 1993; Leonard, et al., 2002) schizophrenics. Additionally,
first degree relatives of schizophrenic patients have shown these same deficits (Adler et
al., 1992) while no studies to date have been done on PPI deficits in relatives of
schizophrenic patients.
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Kumari and Postma (2005) point out from their review of the literature that nicotine
has been shown to enhance PPI in animal studies and in studies involving both healthy
smokers and schizophrenic smokers, but not in non-smokers. George et al., (2006)
verified the finding of an effect of nicotine in schizophrenics but no effect in normals.
However, one study conducted by Kumari, Cotter, Checkley and Gray (1997) did show
that high dose nicotine, delivered subcutaneously, enhanced PPI in healthy nonsmokers. This result has implicated a low-affinity nicotinic receptor (discussed in detail
later).
Two studies related to auditory gating, as measured by the P50 wave, (Adler et al.
1992; 1993) produced interesting results. In the first of the Adler et al. studies (1992),
relatives of schizophrenics who were not diagnosed with schizophrenia and who were
not being treated with antipsychotic medications but who exhibited auditory gating
deficits were given nicotine gum to determine nicotine’s effect, if any, on their auditory
gating deficits. The results showed transient normalization of their auditory gating deficit
(Adler et al., 1992). In the second study by Adler et al. (1993), the effects of nicotine on
schizophrenic smokers and smokers in the normal population were examined. The
results of this study showed that smoking, at a self-selected rate, produced transient
normalization of the auditory gating phenomenon in the schizophrenic group, while the
same smoking behavior in the non-diagnosed population resulted in slight impairment of
auditory gating (Adler et al., 1993). These studies are significant in that it shows a
differential effect of nicotine on auditory gating between non-diagnosed and
schizophrenic populations and suggests a shared neurobiological deficit between
schizophrenics and their first degree relatives.
Eye movement abnormalities
Two eye movement tasks dominate the relevant literature; 1) smooth pursuit eye
movement (SPEM), and 2) antisaccade tasks. SPEM tasks involve presenting a subject
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with a small object, typically a dot on a computer screen, and asking the subject to follow
the object with their eyes while not moving their head. Pursuit accuracy is the
performance measure of interest. Antisaccade tasks, as the name suggests, requires
the subject to inhibit the natural inclination to saccade toward a target, and instead to
begin a saccadic eye movement in the opposite direction, thereby providing a measure
of inclination to saccade toward the target versus the instructed goal of looking in the
opposite direction ( Kumari & Postma, 2005). While studies have shown both impaired
SPEM and increased antisaccade errors in schizophrenia patients versus healthy
controls, nicotinic effects on these tasks may be by different mechanisms. Nicotine
appears to more consistently improve SPEM performance in schizophrenia patients than
in healthy control smokers. When nicotine has been shown to improve SPEM in healthy
control smokers as well as schizophrenic smokers, leading or anticipatory saccades
(said to represent maximized inhibition and reducing intrusions) were only shown to be
improved (by reducing the frequency of leading saccades) in the diagnosed patients,
while healthy control smokers showed impaired performance on the same task (Olincy,
Johnson, & Ross, 2003).
The literature on antisaccade studies is smaller than on SPEM but appear to point to
nicotine improving performance in both schizophrenic smokers and healthy control
smokers. Further, PPI, auditory gating, and SPEM performance have been found to
correlate with each other but not with antisaccade performance (Kumari & Postma,
2005; Kumari et al. 2005). P50 gating performance has also been shown to correlate
with sustained attention and vigilance performance. While none of these measures were
shown to correlate with either negative or positive symptoms of schizophrenia,
antisaccade error rate has been found to correlate with severity of negative symptoms
(Ettinger et al., 2004). Kumari and Postma (2005) suggest anti-saccade performance
may be related to frontal cortex dopamine while the other performance measures are
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thought to be related to a7 nicotinic receptors ( to be discussed in further detail later) and
normalization of hippocampus dysfunction in patients diagnosed with schizophrenia
(Tregellas, Tanabe, Martin, & Freedman, 2005).
Cognitive deficits
Sandyk (1993) provided the first rudimentary evidence that nicotine has a positive
influence on cognition in schizophrenics by simply showing that schizophrenic smokers
performed better than schizophrenic non-smokers on the Mini Mental Status Exam
(M MSE). The M M SE assessed ability related to orientation, immediate memory, and
awareness.
As neuroleptic treatments can also cause cognitive deficits (Levin, Wilson, Rose, &
McEvoy, 1996), Levin et al. (1996) conducted a study to determine if nicotine only
attenuated deficits caused by haloperidol or if nicotine caused performance increases
beyond the mere attenuation of neuroleptic-induced deficits. The subjects were
schizophrenic smokers who had been abstinent overnight. Each was assigned to four
different sessions in which they received a placebo, 7 mg, 14 mg, or 21 mg skin patch
on each of the four different occasions. Additionally, the subjects were divided into three
groups according to haloperidol dose: low-dose (one-third of the neuroleptic threshold
(NT) dose), medium (NT dose) and high (three times NT dose). Subjects were tested
using four tests from the Automated Neuropsychological Assessment Metrics (ANAM)
battery: simple reaction time, complex reaction time (spatial rotation), delayed-matchingto-sample (DM TS), and a modified Sternberg Memory Test. After the ANAM battery,
subjects were administered the CPT. The results showed no effects of nicotine or
nicotine x haloperidol on simple reaction time or the modified Sternberg Memory test.
On complex reaction time haloperidol significantly slowed RT while nicotine significantly
improved RT. On this measure nicotine not only attenuated the haloperidol-induced
deficits but had a reversal effect. For the DMTS procedure nicotine was found to
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reverse the decrements caused by medium and high dose haloperidol. On the CPT, RT
was improved with the 7 mg and 14 mg dose of nicotine but slowed with the 21 mg patch
irrespective of haloperidol dose. The results of this study show that while schizophrenics
receiving typical neuroleptic treatments may smoke in part to relieve neuroleptic-induced
deficits, the performance enhancing effects of nicotine are superfluous to these deficits.
A study by White and Levin (1999) provide additional evidence of nicotine’s effect on
attention and vigilance in diagnosed populations. These researchers examined the effect
of a 5 and 10 mg nicotine patch on performance of the CPT in non-smoking patients with
Alzheimer’s disease (AD). AD patients are of interest because they share a receptor
deficit with schizophrenic patients, a loss of nicotinic acetylcholine receptors (this deficit,
and other neurotransmitter theories, are discussed later in this paper). White and Levin
(1999) used the same measures and design as the Levin et al. (1996) study. The
results showed that nicotine reduced errors of omission, RT variability, and total errors
on the C P T while improving the C P T ’s composite measure of attention (d’). The authors
note that nicotine’s effect on the C P T has been observed in AD, schizophrenic, and
normal populations and thus represents a notably robust and consistent finding.

Differential effects between diagnosed and non-diagnosed populations
Evident from some of the studies discussed above, the effects of nicotine appear to
be different for diagnosed versus non-diagnosed populations. Additional studies
demonstrate such findings more explicitly. For example, George, Vessicchio, et al.
(2000) showed differential effects of nicotine between diagnosed and non-diagnosed
populations. They examined the effects of acute (<1 week) and prolonged (8-10 weeks)
nicotine abstinence on the Stroop Color-Word Test and the Visual Spatial Working
Memory (VSW M ) test in nicotine-dependent and control schizophrenic and nondiagnosed populations. The results showed no effect of smoking status in either group
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on the Stroop test. Non-diagnosed smokers were shown to have impairments on the
VSW M task as compared to non-diagnosed non-smokers while schizophrenic smokers
were shown to have slightly improved VSW M function compared to non-smoking
schizophrenics. Furthermore, smoking abstinence led to impaired V SW M function in
schizophrenic smokers and to an improvement in V SW M function in non-diagnosed
smokers. Further evidence for nicotine impairing spatial working memory in nondiagnosed smokers was provided by Park, Knopick, McGurk, and Meltzer (2000). Myers
et al. (2004) found that nicotine delivered via nasal spray significantly improved delayed
recognition on a visuospatial task for smoking schizophrenics but had no significant
impact on non-smoking schizophrenics or smoking or non-smoking controls. Likewise,
Smith et al. (2006) demonstrated that nicotine nasal spray resulted in modest
enhancement of spatial working memory in schizophrenic smokers. This same study
found no effect of nicotine on verbal memory. O f note, while the Myers et al. (2004)
found an effect on the visuospatial recognition of design test, they found no effect on a
non-verbal working memory task involving delayed matching-to-sample of unfamiliar
faces. Harris et al. (2004) found no effect of nicotine administered via gum to smoking
and non-smoking schizophrenics on visuospatial, immediate or verbal delayed memory,
but again found nicotine to have an overall impact on the attention measure. O f interest,
the overall effect on attention appeared to be due to an increase in performance in nonsmokers and a decrease in smokers, suggesting an inverted-U or optimization effect of
nicotine even in diagnosed populations.
Depatie et al. (2002) investigated the effects of a 14 mg nicotine patch on CPT
(Cornblatt, 1988 version), antisaccade, and smooth pursuit performance in
schizophrenic and normal smokers. These authors included type of antipsychotic
medication, presence of anticholinergic medication, order of drug administration
(nicotine/placebo vs. placebo/nicotine) and Positive and Negative Syndrome Scale
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(PANSS) scores as factors in their statistical analysis. Subjects in both groups were
abstinent for 9 hours prior to receiving either a 14 mg nicotine or placebo patch. Testing
commenced 7 hours following patch administration to assure testing coincided with
plateau nicotine levels. Results revealed no significant effect of type of medication,
presence of anticholinergic medications, order of drug administration, or PANSS score
on the performance measures. Adler et al. (1993) and Green et al. (1997) also found
anitcholinergics to play no intervening role between nicotine and auditory gating nor
nicotine and CPT performance, respectively. C P T results showed nicotine to increase
hit rate (correct responses) in schizophrenics but not in normals; additionally, it was
found that the increase in hit rate in schizophrenics was not significantly different
between the first half and last half of the test indicating that nicotine did not improve hit
rate by simply preventing a decline in performance over time. Nicotine also improved
performance on the composite measure of attention (d’) in both groups. No other
significant effect of group or drug was found on this measure. Nicotine was found to
improve performance on the antisaccade and smooth pursuit measures in both groups.
This study (Depatie, et al., 2002) provides partial evidence for a differential effect of
nicotine between schizophrenic and normal populations.
O f particular interest regarding differential effects of nicotine by population are two
very well designed studies by Sacco and colleagues (2005; 2006). In the first study
(Sacco et al., 2005) the effects of overnight abstinence on CPT and VSW M were
observed in 25 smokers with schizophrenia and 25 control smokers. These authors also
examined the effects of nicotine reinstatement and the effect pretreatment with the nonselective nicotinic-acetylcholine receptor (nAChR) antagonist (mecamylamine
hydrochloride 0, 5, or 10 mg/d) would have on nicotine reinstatement. The results
showed nicotine abstinence to impair CPT hit rate performance in both groups while
V SW M was only impaired in the smokers with schizophrenia. Smoking reinstatement
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reversed these impairments, however mecamylamine was found to block the
reinstatement effects (dose-dependently on the CPT) only in the schizophrenia group,
suggesting that nAChRs play a role in attentional and V SW M enhancement in
schizophrenics. Of interest, the more subjective Positive and Negative Syndrome Scale
was unaffected by mecamylamine administration, perhaps suggesting different
neurocircuitry involvement for traditional positive and negative symptomology.
Of further interest is the second study conducted by Sacco et al. (2006) in which they
evaluated neuropsychological deficits in non-smokers with schizophrenia compared to
non-smoking controls. The authors tested the subjects at baseline on V SW M , CPT,
W CST, Word Serial Position Test (W PST) and a Stroop (SCW T) task and then again
over 3-days on three separate testing weeks after being administered mecamylamine 0,
5, or 10 mg/d. The authors found that the schizophrenia group had baseline
neuropsychological deficits on VSW M , CPT (%Hit Rate, Reaction Time, and Variablity
Index), W C ST, and W SPT, while subsequent mecamylamine administration had no
significant effect on performance in either group. This study, considered together with
the Sacco et al. (2005) and other studies, suggests that smokers, particularly diagnosed
smokers, may possess different receptor dysfunction than their non-smoker
counterparts. Upregulation of high-affinity nAChRs have been shown to occur dosedependently in non-diagnosed smokers compared to their non-smoking counterparts.
This upregulation was not observed in smokers with schizophrenia (Breese et al., 2000).
It is likely that mecamylamine, a non-selective nAChR antagonist, was not exerting
enough of an influence on the low-affinity nAChRs (Freedman et al., 1994) implicated in
some of the neurocognitive deficits in schizophrenia. Research utilizing more selective
nAChR antagonists is needed.
The psychological/neurocognitive evidence reviewed herein shows that nicotine does
affect certain cognitive constructs and further that there exists evidence for a differential
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effect on diagnosed versus non-diagnosed populations, thus providing some support for
the hypothesis that schizophrenics smoke at a higher rate due to an attempt to mitigate
cognitive deficits. Neurobiological evidence in support of this hypothesis is discussed
below.

Schizophrenia, neurotransmitters, cognition, and nicotine
Although many different neurotransmitters are implicated in playing a role in the
etiology and course of schizophrenia (Lyon, 1999), most research has focused on
dopamine (DA) (Diwan et al., 1998; Green, Zimmet, Strous, & Schildkraft, 1999; Goff et
al., 1992; Lyon, 1999; Sandyk & Kay, 1991; Ziedonis & George, 1997). Meltzer and
Stahl (1976), along with Carlsson (1978), were among the first to put forth the dopamine
hypothesis of schizophrenia. In its most rudimentary form, the dopamine hypothesis
states, “schizophrenia may be related to a relative excess of DA-dependent neuronal
activity” (Meltzer & Stahl, 1976, p. 19). These early theories dealt primarily with the
positive symptoms of schizophrenia and evidence was derived from the DA targeting
pharmacological treatments such as chlorpromazine and haloperidol. A more refined
DA theory implicates hyperactivity of DA synapses in the mesolimbic pathway, which
projects from the ventral tegmental area (VTA) to the nucleus accumbens (NA) and
amygdala, as responsible for the positive symptoms of schizophrenia; while hypoactivity
of DA in the dorsolateral prefrontal cortex is thought to be responsible for the negative
symptoms of the disease.
As noted earlier, cognitive deficits are now considered the core feature of
schizophrenia, and dopamine is again thought to play a role (Meltzer, 1999c). However,
in looking at how nicotine improves cognitive performance, dopamine’s role appears
secondary to nicotine’s effect on the cholinergic system. Nicotine intake acts on the
cholinergic innervations of the ventral tegmental area (VTA) and the substantia nigra
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(SN) (both of which are important for working memory function); this results in an
increase in ACh input which in turn increases DA activity in these areas, and most
importantly in the frontal cortex (Levin, Briggs, Christopher, & Auman, 1994). Dopamine
D2-receptor agonists have been shown to improve memory when co-administered with
nicotine, but D2 agonists alone had no effect (Levin, McClernon, & Rezvani, 2006).
Nicotine binds to cholinergic nicotinic receptors and results in the release of ACh
(Pineda et al., 1998). In aged and demented human subjects, aged rats, and in AD
patients a relationship between cholinergic degeneration and various decrements in
cognitive functioning has been found, Bartus, Dean, Beer, & Lippa and Collerton (as
cited in Giovannini, Casamenti, Bartoloni, & Pepeu, 1997). O f particular interest are the
nicotinic-ACh receptors (nAChRs) present in the hippocampus and frontal cortex, as the
prefrontal cortex and hippocampus are known to be essential for cognition (Meltzer,
1999c). There are numerous subtypes of nAChRs (see Dani, 2001 for a comprehensive
review), but a402 and a7 are predominant in the mammalian brain. Mansvelder, van
Aerde, Couey, and Brussaard (2006) note that the a7 subunit is even more widely
expressed in primates than lower mammals such as rats suggesting that the oc7
receptors play a more important role in humans. Both a402 and a l nicotine receptors in
the hippocampus are important for cognitive functioning (Levin & Simon, 1998), but the
primary function of the a402 receptors appears to be the release of DA in the
mesolimbic system, thereby contributing to the reinforcing effects of nicotine (Foulds,
2006). The reinforcing effects of nicotine are separate from nicotine’s memory
enhancing effects, Grigoryan, Hodges, Mitchell, Sinden, and Gray (as cited in Levin &
Rezvani, 2000). Most authors conclude that the a l receptors are particularly important
for cognition (Adler et al., 1998; Dani, 2001; Levin & Rezvani, 2006; Mansvelder et al.,
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2006). As such, the remainder of this section will focus on the evidence for this
conclusion.
Post-mortem studies of schizophrenics have shown a deficient number of a l
receptors in the frontal cortex (Levin & Rezvani, 2006). In the mouse brain nicotine and
ACh have been shown to cause a marked increase in glutamate release in layer V of the
frontal cortex (Lambe, Picciotto, & Aghajanian, 2003), which has been shown to be
important for cognitive function (Levin et al., 2006). MRI studies have also shown that
nicotine’s attentional improvements are related to activity in several regions of the cortex
including the superior frontal cortex (Levin et al., 2006). Infusion of nicotine in the frontal
cortex has been shown to improve choice accuracy (presumed to involve attention) on
the 5-choice serial reaction time task (5-CSRTT) in rats (Hahn, Shoaib, & Stolerman,
2003), which again implicates the involvement of nicotine receptors in the frontal cortex
in improving attentional performance (Levin et al., 2006). Studies also show that
decreased ACh in the frontal cortex impairs attentional functioning (Mansvelder et al.,
2006). The exact location of the a l nicotinic receptors in the frontal cortex that are
responsible for attention are unknown (Mansvelder et al, 2006), but there does exist
sufficient volume of evidence to say with confidence that nicotinic effects in the frontal
cortex have an impact on cognition.
Most neuroimaging studies have found reduced hippocampal volume in
schizophrenics (Heckers, 2001; Tanabe, Tregellas, Martin, and Freedman, 2006). In
post-mortem studies, schizophrenics have been shown to have a deficient number of a l
receptors (Freedman, Hall, Adler, & Leonard, 1995; Leonard et al., 1996; Levin et al.,
2006), as well as a4|32 receptors (Durany et al., 2000), in the hippocampus.
Administration of an ACh depleting neurotoxin (AF64a) directly into the hippocampus
resulted in severe learning and memory impairment (Hiramatsu, Yamatsu, Kameyama,
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& Nabeshima, 2002)). Induction of Long-term potentiation (LTP: the neural substrate of
working memory) via nicotinic stimulation of glutamatergic synapses in the hippocampus
has been shown to influence learning and memory (Mansvelder et al., 2006). Levin et
al. (2006) cite a wide array of specific evidence that the a7 receptors in the
hippocampus are responsible for the effects of nicotine on cognition, including animal
and human studies that link performance on a measure of associate learning (eye-blink
procedure) to a l receptors in the hippocampus. Particularly interesting, Levin et al.
(2006) report that when either a4(32 or a7 antagonists are injected into the rat
hippocampus, memory impairment in the radial-arm maze results. However, chronic
nicotine injections reverse the adverse effect of a4(B2 blockade on memory but does not
reverse the effects of a7 blockade, suggesting that the full activation of hippocampal
a4p2 is not necessary for memory and that hippocampal a7 receptors are primary to
nicotine’s positive effects on memory.
It is difficult to discern a clear picture of distinct effects, due to specific nAChRs, in
specific brain regions; and it should be noted that the research in this area is not at a
point where direct causal relationships can be drawn. Several of the previously
referenced authors discuss reasons why specific conclusions are still yet to be made,
those include; the lack of good receptor specific pharmacological compounds, lack of
consistent methodologies, technological limitations, and potential developmental
compensations in transgenic animals (see Mansvelder et al., 2006 and Gotti et al., 2006
for a more detailed discussion). It was noted earlier that nAChRs are distributed widely
throughout the brain, and differently in primates than other lower mammals. It is also a
fact that even though one nAChR subtype may predominate a brain region, other
nAChRs may coexist (Dani, 2001); and even a relatively small number of nAChRs can
have large effects on neural systems. Although a7 nAChRs are of primary interest to the
current topic, authors have also shown a432 agonists to improve working memory and
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attentional accuracy (Levin et al., 2006). In addition to their effects on DA release in the
mesolimbic system, 0402 receptors have been implicated in cognitive deficits related to
low DA activity in the PFC. Further, neither nAChRs nor brain regions work in vacuums
that prevent them from affecting other regions of the brain. For example, several of the
authors reviewed have pointed to nAChR interactions with glutamate, GABA, dopamine
and serotonin; and Heckers (2001) points to hippocampal and frontal lobe interactions.
Despite the challenges and need for refinement of data, a picture with both good
research support and good face validity is beginning to emerge. This involves specific
regions of the hippocampus and differential effects in regard to receptor desensitization
between populations. Chronic administration of nicotine increases the number of
nAChRs (upregulation) in the hippocampus, (Marks, Stitzel, & Collins study as cited in
White & Levin, 1999; Levin & Rezvani, 2000) and may produce long-term structural
changes in the density and/or sensitivity of nAChRs in the frontal cortex (Pineda et al.,
1998). Breese et al, 2000 reported a robust finding of upregulation of nAChRs in highaffinity receptors and a less robust finding of upregulation of low-affinity nAChRs in the
non-diagnosed group but not in schizophrenica group, providing biological evidence for
nAChR differences in schizophrenics. Freedman et al. (1995) reported finding a lower
number of a.7 receptors in the dentate gyrus, CA3 and CA1 regions of the hippocampus
in schizophrenics independent of smoking status, again suggesting normal upregulation
does not occur in this population. Mansvelder et al. (2006) discuss findings that show
desensitization differences between a4(32 and a7 nAChRs. Stimulation via direct
synaptic or indirect non-synaptic actions results in activation and rapid desensitization of
these receptors. Mansvelder et al. (2006) state that the physiological significance of
high-affinity (a4(B2) and low affinity (a7) subtypes may not be in their activation
properties but in their desensitization.

Low concentrations of nicotine activate both
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receptor systems (except for a7 receptors in the VTA), but the a4|32 are completely
desensitized at this level while a7 receptors are not and remain available for activation.
These findings support many authors’ theories that hippocampal dysfunction, and
possible altered nAChR response in this area (Jacobsen et al., 2004), is involved in both
the cognitive impairment and symptomology in schizophrenia (Venables, 1992;
Hemsley, 1993; Roberts; 1963, as cited in Heckers 2001). One predominate and
research-supported theory is that a7 nAChRs in the hippocampus show decreased
desensitization (Levin and Rezvani, 2006) and interfere with the ability to distinguish
relevant from irrelevant information, and internal cues from external cues (Heckers,
2001). Nicotine may improve this situation and enhance working memory by reducing
distractibility (Levin et al., 2006) via nAChRs that increase the signal-to-noise ratio, and
helping the process of evaluating the significance and relevance of received stimuli
(Dani, 2001). In fact, Tregellas, Tanabe, Martin and Freedman (2005) showed that
nicotine-induced performance improvement on a SPEM task was correlated with
decreased activity in the hippocampus and contend that nicotine activated nAChRs that
normalized hyperactivity in this region and prevented intrusive saccadic eye movements.
The CA 1 and CA3 regions of the hippocampus are specifically implicated in both the
neuropathology and the modulation of cognitive impairment by nicotine. Levin et al.
(2006) state that long-term potentiation (LTP) in the CA1 region of the hippocampus is
the neural substrate of learning and memory and that ACh lesions here impair LTP while
nicotine reverses this effect and additionally promotes LTP. Mansvelder et al. (2006)
state that the CA1 pyramidal neurons in the ventral hippocampus project to the PFC,
and hypothesize that modulation of the CA1 region by nicotine may be at least in part
responsible for the effect of nicotine on attentional performance. Additional evidence for
the involvement of these regions of the hippocampus and a7 nAChRs have been
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provided via research on sensory gating. This research and an eloquent hypothesis
provide by L.E. Adler will complete this section.
The sensory gating deficit (P50) in humans discussed previously has been linked to
a7 deficits in the hippocampus (Adler et al., 1998). Additionally, a7 agonists have been
found to increase gating of the analogous P20-N40 auditory-evoked potential (AEP) in
rats. This information has resulted in the hypothesis that a deficient population of a l
receptors in the hippocampus results in inadequate stimulation of inhibitory neurons and
results in sensory gating deficits (Simosky, Stevens, Adler, & Freedman, 2002). Nicotine
acts on these neurons and maintains them in an activated state producing an inhibitory
effect and normalizes this deficit (Mancuso, Warburton, Melen, Sherwood, & Tirelli,
1999). Adler et al. (1998) present the most eloquent theory on how this may occur.
Adler et al. (1998) explain sensory gating as a way for the brain to filter input by
habituating to identical stimuli and only attending to the most important information. The
authors focus on the CA3 region of the hippocampus because, among other reasons,
this is the major point of convergence for cortical and brainstem inputs. Information that
reaches the CA3 region projects to CA1 pyramidal neurons; the CA1 region is the site
for LTP or extended short-term memory. CA1 deficits cause a nearly complete loss of
new learning. The CA3 region filters irrelevant and repetitive stimuli and prevents them
from getting output to the CA1 region; in effect it prevents flooding. When CA3 gating
fails, it results in a decrease in learning efficiency, and in fact, incorrect learning may
occur by attending to the wrong stimuli. The authors contend that the resulting
attentional and learning decrements may be responsible for the low social functioning
prevalent in schizophrenics.
Additional evidence for the centrality of a l receptors in explaining why
schizophrenics smoke at a higher rate comes from the smoking behavior of this
population. High affinity nicotine receptors (a2,-3,-4,-5 & (32,-3,-4) are activated by low
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dose nicotine, while low affinity receptors (a7) are activated by high dose nicotine.
Schizophrenics have been shown to smoke high nicotine cigarettes, extract more
nicotine from the smoke, and smoke more cigarettes (Adler et al., 1998). It is proposed
that normal smokers hit the high affinity receptors that result in the decreased anxiety
and elevated mood that may be partially responsible for smoking in this population. The
higher dose of nicotine, self-selected by schizophrenics, may be an effort to target the
low affinity a7 receptors and normalize the corresponding deficits. Evidence for this was
provided in Adler et al. (1992) where low dose nicotine failed to normalize P50 gating
while high dose nicotine did. Additionally, Freedman et al. (1994) gave first-degree
relatives of schizophrenics with P50 gating deficits both high-dose nicotine and
mecamylamine and found the P50 gating deficit to be normalized , again implicating the
low affinity nicotine receptors since it has been shown that mecamylamine blocks the
effects of low dose nicotine. Freedman et al. (1997) also found genetic evidence for the
presence of a7 deficits in schizophrenics. In sum, there is a preponderance of evidence
taken from schizophrenics, their first degree relatives, and animal studies that sensory
gating deficits involve a l receptors in the hippocampus and that nicotine normalizes
these.
Finally, there is evidence that clozapine, which increases extracellular ACh in the
medial prefrontal cortex, reduces smoking in schizophrenics (Meltzer, 1999c). Further, a
recent study (Simosky, Stevens, Adler, & Freedman, 2003) showed that clozapine
normalized inhibitory processing of the P20-40 (AEP) in mice via stimulation of a7
nicotinic receptors. Of interest is research showing 5-HT2a receptor blockade reduces
the enhancing effects of nicotine on attention and memory (Levin et al., 2006), so it
raises the question that clozapine may reduce smoking because smoking no longer
attenuates the attentional and memory impairments associated with schizophrenia.
Levin and Rezvani (2006) state it has been suggested that drugs such as clozapine
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which do block 5-HT2 receptors may limit the efficacy of nicotine co-treatment for
cognitive enhancement.
To be sure, this section does not constitute a full discussion of all the mounting
evidence for the involvement of nAChRs in cognition, their connection to the cognitive
impairment in schizophrenia, and the reversal of those impairments via smoking.
However, the reader should have a good introduction to the topic an related issues. The
reader can turn to the afore-referenced articles by Mansvelder et al., 2006; Dani, 2001,
Levin and Rezvani, 2006; Levin, McClernon and Rezvani, 2006; and Heckers 2001 for
comprehensive reviews including discussions of the challenges of isolating responsible
brain regions and receptors.

The reader should turn to Robert Freedman and Sherry

Leonard , previously referenced, for information regarding genetic evidence for links
between a7 deficits, schizophrenia, and cognitive dysfunction.

Summary
Of the competing hypotheses that attempt to explain the differential prevalence of
smoking in the schizophrenic population, the self-medication hypothesis, specifically the
mitigation of cognitive deficits, garners the most empirical support. Neuropsychological
studies have shown that nicotine does in fact enhance performance on certain cognitive
constructs over and above the simple mitigation of withdrawal or fatigue states. Clinical
studies show the cholinergic system, specifically hippocampal a7 receptors, to be both
involved in cognitive performance and stimulated by nicotine. Differential effects
between normal and schizophrenic populations may be related to a7 deficits within the
schizophrenic population.
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Specific aims o f the present study
As the above discussion reveals, the amelioration of cognitive and attentional deficits
is currently the most promising explanation for the higher prevalence of smoking among
schizophrenics compared to the general population. But the term cognition is too
general to be of practical use; Green (1996) corroborated this when he reviewed the
literature in this area and found it to be too global. The present study focused on those
components of cognition that have been shown to be important for social functioning.
Green (1996) reported the most consistent finding in the schizophrenia literature is that
vigilance is important to both skill acquisition and problem solving, while verbal memory
(most frequently secondary, but immediate as well) was the most consistent predictor of
functional outcome. Additionally, research conducted by Herbert Y. Meltzer’s group at
Vanderbilt University Medical Center shows a strong association between immediate
and delayed recall (a common measure of verbal memory) and this population’s ability to
work (unpublished data). The present study was designed to test the effect of nicotine on
these specific cognitive and attentional constructs. Specifically, data were collected to
test the following hypothesis: determine if healthy smokers’ scores on the RAVLT (sub
measures trial 5 (RVLTV), total for trials 1-5 (RVLTTT), delayed recall trial 7 (RVLTVII),
correct recognitions (RVLTCORREC), and recognition discriminations
(RVLTRECDISCR); and the CPT (raw scores for all 13 sub-measures, and three test
factors Impulsivity, Inattentiveness, and Vigilance based on combined T-scores from
relevant sub-measures) will be significantly different in the acute-abstinence session
from the free-smoke session.
Although the high rate of smoking in schizophrenics was the impetus for this line of
inquiry, and much of the literature review concerned nicotine effects in schizophrenia,
the review of nicotine effects in non-diagnosed controls provides the rationale for the
current study.
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Regarding effects on verbal memory, while the studies reviewed were creative in
testing various aspects of verbal memory, most failed to use standardized assessments
for immediate and delayed recall. Also, most of the studies used delivery mechanisms
other than smoking to assess the effects of nicotine (the importance of delivery
mechanism is discussed in the Methods section below). Finally, some of the studies
assessed nicotine effects in non-smokers and provide little help to the task of
determining reasons for the initiation of smoking.. The current study implemented a
standardized and psychometrically sound assessment of immediate and delayed verbal
memory to assess in smokers the impact of nicotine via the participants’ normal smoking
behaviors.
Regarding effects on vigilance, some of the same problems exist here that are seen
in the memory research. The majority of the studies reviewed investigated the effect of
nicotine patch on different measures of attention. Koelega (1993) stated that 11 of 17
studies he reviewed showed some effect of nicotine on attention. This paper reviewed
an additional 10 studies yielding 19 out of 27 studies showing some effect on a measure
of attention. However five of the 11 studies that Koelega (1993) referenced also showed
no effect of nicotine on other attention variables measured, and two of the studies
reviewed in the current document showed impaired performance on some measure of
attention. So looking at it another way, 15 out of 27 studies revealed either no or a
detrimental effect of nicotine on cognition in healthy controls. Further, as eluded to,
attention has been defined in various ways (some unrelated to vigilance) and the
measures used to assess these constructs have also varied greatly making comparisons
and consensus agreement difficult. As with memory, the current study used a
standardized and psychometrically sound assessment of vigilance, as meaningfully
defined, to assess in smokers the impact of nicotine via the participants’ normal smoking
behavior.
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Participants
Subjects were recruited utilizing Vanderbilt University’s psychology department
research subject pool, Vanderbilt University Medical Center’s (VUMC) mass email
system, word of mouth, and fliers placed around the VUM C campus, Centerstone
Davidson County clinics, and in the internal mailboxes of Centerstone employees.
For inclusion in the study, participants must have been between the ages of 18 and
60, carry no current psychiatric diagnosis, and currently smoke at least 10 cigarettes a
day. The age range was selected to include diverse participants, but the high end of the
range was selected to control for possible cognitive decline as a result of age. For
nicotine levels to be of sufficient strength to possibly affect vigilance and/or verbal
memory tasks, only moderate to heavy smokers (£ 10 cigarettes/day) were included.
Exclusion criteria for participants was any current psychiatric diagnosis including
substance dependence or significant abuse, currently taking psychotropic or smoking
cessation medications, presence of any organic brain injury or neurological disorder, or
history of significant traumatic brain injury.
Out of the over 300 respondents, 14 participants both met the inclusion criteria and
gave consent to participate in the study. Of those, 13 completed the majority of the
study procedures. All subjects were compensated for their time at the rate of $15 per
testing session. Written informed consent was obtained from all participants and all
study procedures were approved by both the Western Michigan University and
Centerstone Institutional Review Boards (IRBs). Additionally, recruitment activities at
Vanderbilt were approved by Vanderbilt following confirmation of study approval by the
aforementioned IRBs.
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The majority of the respondents were expecting a smoking cessation study and were
no longer interested when they learned more about this study. Many others failed to
meet the inclusion criteria due to currently taking smoking cessation and/or
antidepressant medications. Several other prospective participants were unwilling to
abstain from smoking for the required minimum of 6 hours. While the resulting sample
size was small, pre-study power analysis indicated that this sample size should be
sufficient. Sample size was determined using the Statistical Analysis System (SAS)
program using the following values. For power of .80 and type-1 error (alpha) of .05 to
detect a difference of .8 (taken from previous study) with a population variance (sigma)
of 1.06 (also taken from previous study) and with a correlation between measures of 0.5
or 0.7, a sample size of 15 or 9 was needed, respectively.

While more participants were

desired, previous studies with similar sample sizes, using clinical populations, have
found significant effects of nicotine on attention and memory, making comparisons with
the current findings of interest in looking at effect size differences between normal and
clinical populations.

Materials
As stated in this paper’s introduction, vigilance and verbal memory are the two
areas of cognition most consistently related to individual and social functioning in
schizophrenics (Green, 1996; Meltzer, unpublished data). Vigilance is often equated
with attention and all too frequently vaguely defined, if defined at all. Vigilance can be
differentiated from attention in general. Mateer and Mapou (1996) provide
subcategories of attention that they refer to as deployment and encoding. Vigilance is
subsumed under the deployment subcategory. Lezak (1983) defines vigilance as the
ability to sustain attention. This is the more precise definition of vigilance and will be
used as the definition for the construct under investigation in this study.
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Memory is a complex construct, which while it has been compartmentalized, it is not
always easy to maintain these subdivisions in a meaningful manner. For the purposes
of this study (verbal) working memory will be subsumed under Mateer and Mapou’s
(1996) subcategory of attention, referred to as encoding. Additionally, Spreen and
Strauss (1998) refer to the type of memory we are interested in (immediate and delayed
verbal recall) as explicit memory, which is frequently tested through the recall of word
lists. Explicit memory is said to involve the hippocampal system, which has already
been demonstrated to be important in the way nicotine facilitates memory, and deficits in
this region have been observed in schizophrenia and other diagnosed populations.
Dysfunctions of this system often result in the disruption of “the formation/retrieval of
new explicit memories” (Spreen & Strauss, 1998, p. 260).
Levin et al. (1996) correctly assert that the nature of the task used to assess the
construct critically influences the results. In literature reviews conducted by Koelega
(1993) and Heishman (1998) both authors conclude that measures used to assess
vigilance vary greatly and have low intercorrelations. Further, both authors state that
many of the studies use tests that are not standardized, lack or fail to report validity and
reliability data as well as administration procedures.

The current study addresses these

concerns.
The Conners’ Continuous Performance Test-ll (2002) was used in this study to
assess the primary construct vigilance, and related constructs inattention and
impulsivity. Many tests are used to assess vigilance and attention (for example, the
W AIS-R Digit Symbol Substitution Test, the W A IS-R Digit Span, and the Stroop test);
however, the Conners’ CPT is the only standardized, valid, and reliable measure noted
in the literature to specifically test vigilance as defined for this study. The 1995 (dos)
version of the Conner’s CPT has been used extensively in research and clinical settings
and has shown to be sensitive to drug treatment effects (Conners & MHS staff, 2002); of
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current interest, it has been shown to be sensitive to nicotine and stimulant induced
attentional improvements (White & Levin, 1999; Levin & Rezvani, 2000). Administration
of the C P T (or CPT-II) takes 14 minutes and the subject is asked to press the space bar
on the computer keyboard as quickly as possible when any letter except the target letter
“X ” appears. Inter-stimulus intervals are 1, 2, and 4 seconds distributed randomly within
each of the 6 blocks of the test. A short practice test precedes each administration.
Conners reports that little to no practice effects occur from using the CPT repeatedly
(Conners & MHS staff, 2002). Pritchard, Robinson, & Guy (1992) provide independent
confirmation of this. Conners states that any potential practice effects are most likely
offset by “increased boredom “ that results from a very long repetitive task. Normative
data on the Conners’ CPT (1995) has been collected on a sample of 670 patients with
various attentional disturbances, aged 4 to 61 years and 520 normals, aged 4 to 70
years. Data collected from these samples yield high validity and reliability values
(Conners and MHS Staff, 1995).
The CPT-II (2002) provides data for 13 sub-measures all of which have some
relevance to the study question. Additionally, the test converts raw scores for these sub
measures to age and sex corrected t-scores. Analysis by the test authors reveals that
utilizing the t-scores the 13 sub-measures may be grouped into indicators of inattention,
impulsivity, and vigilance. Having age and sex corrected t-scores readily available, and
having multiple sources contribute to the constructs of interest are additional factors that
make the CPT-II ideal for the present study.
The major differences between the Conner’s C P T (1995) and the Conner’s CPT-II
(2002) are the operating system platform (Windows for the CPT-II), broader norms for
the CPT-II, and improved psychometric properties related to administration validity
checks. Normative data on the CPT-II were collected on 2686 patients and non
patients. Data provided from these samples show the CPT-II to possess the same
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desirable psychometric properties as the original Conner’s C P T (1995) version. There
do exist some technical differences in the way some of the sub-measures of the CPT-II
are calculated and reported, however these differences do not impact the results of this
study nor there interpretability in relation to previous C P T studies.
To assess verbal memory, this study utilized the Rey Auditory-Verbal Learning Test
(RVLT) (Rey, 1958; Taylor, 1959; Lezak, 1976, 1983). The RVLT is a commonly used
test of verbal learning and memory. It provides a wide range of norms (7 - 88 year olds),
has standardized administration procedures, and is psychometrically sound.
Administration of the test involves the examiner reading a 15-word list at a rate of one
word per second: immediately after which the subject is asked to recall as many of the
words from the read list as possible. This process is repeated 5 times (Trials 1 -5). This
portion of the test assesses the verbal working (immediate) memory construct of current
interest. Immediately following trial-5 the subject is read a second 15-word list and then
asked to recall the words from the first list. This trial, trial 6, is a distracter task.

No

construct of current interest is assessed by this trial. Following trial 6 the subject
engaged in an alternate activity (CPT-II + 6 minutes) for 20 minutes and was then asked
to recall as many words from the first list as is possible (trial 7; RVLTVII); thus assessing
delayed verbal (secondary) memory. Following trial 7, the subject is given a list of 50
words which include words from the first list, the distracter list, and additional words not
previously seen as part of the test, and asked to circle the words from the first list. This
trial yields number of correct recognitions (RVLTCOR REC) and percentage of
discriminations (RVLTRECDISCR) derived from correct recognitions + correct rejections
divided by 50 X 100. Spreen and Strauss (1998) state that the RVLTV, RVLTTT, and
RVLTVII sub-scales assess the retrieval component of verbal memory while the
RVLTCO RREC and RVLTRECDISCR sub-scales assess the storage component.
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There have been numerous normative studies for the RVLT, but the metanorms
provided by Schmidt (1996) are appropriate and were used for the administration
procedures chosen for this study. This test has been used extensively in both normal
and clinical populations (including psychosis) and has shown to be sensitive to verbal
memory deficits in both populations (Spreen and Strauss, 1998). The specific constructs
assessed by the RVLT, use with similar populations, presence of standardized
administration procedures, and desirable psychometric properties make it suitable for
use in the present study. O f note, practice effects of 1 -2 word improvements upon
repeated administration have been noted. The counterbalance design of this study and
the >1 week interval between administration points helped removed this as a
contributing variable.
Additional material used in this study was a participant demographics questionnaire
that included basic demographic questions along with questions regarding the
participant’s current medication regimen and smoking history. The Fagerstrom Test for
Nicotine Dependence (FTND; Heatheron, Kozlowski, Frecker, and Fagerstrom, 1991), a
six-item self-report questionnaire, was also given to verify smoking status and gauge
level of addiction.

Design and procedures
Following initial contact, interested participants were first scheduled for a screening
visit where informed consent was obtained and screening and demographic documents
were completed along with the FTND.

A copy of the singed consent form was given to

the subject and the investigator retained the original.
The study employed a counterbalanced (crossover) repeated-measures design.
This design controlled for order effects related to nicotine condition (abstinence orfreesmoke), possible effects of time, and any practice effects related to the dependent
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variables.

At the end of the screening visit, participants were randomly assigned to

which nicotine testing condition they would participate in first. Each participant engaged
in testing in the “free-smoke” and the smoking abstinence condition.
As Levin et al. (1996) assert, regimen (and route) of nicotine administration critically
influences the outcome in studies examining the effects of nicotine.

Thornton et al.

(1996) and Heishman (1998) both state that the use of differing routes of nicotine
administration complicates interpretations and makes comparisons difficult. The use of
nicotine skin patch or nicotine gum gives the investigator the advantage of being able to
determine the exact amount of nicotine the participant will ingest. However, the
pharmacokinetics of these routes vary greatly from those of cigarette smoking
(Mancuso, Andres, et al., 1999). Most authors now suggest that in order to study the
effects of smoking on cognition that you must use nicotine via smoking inhalation as the
delivery mechanism (Olincy, Johnson, and Ross, 2003). Since the primary interest of
this study is cigarette smoking and there exists evidence that low affinity a7 nicotine
receptors are involved (neither nicotine patch nor gum approximate the peak nicotine
levels achieved via smoking), cigarette smoking at the participants self-selected rate was
used as the route of administration. In an excellent review of nicotine dose and delivery
selection in research, Matta et al. (2007) note that use of delivery mechanisms that
result in slowly rising nicotine levels may result in desensitizing certain nicotinic
receptors without first depolarizing them. The same authors state that cigarette smoking
is the most efficient means of rapidly delivering nicotine to the brain. Using the
participant’s typical delivery mechanism and their typical rate of ingestion addresses the
question if nicotine as typically used improves performance on our chosen measures. A
full review of the nuances related to the pharmacokinetics of nicotine delivery is beyond
the scope of this paper; however the interested reader should turn to the Matta et al.
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(2007) paper previously referenced and another excellent summary by Hukkanen, Jacob
III, and Benowitz, 2005.
Both presence and absence of nicotine was determined immediately prior to
assessment using the EC50-Micro III Carbon Monoxide Monitor (Bedfont Scientific, NJ ).
The assessments for both conditions were conducted at the same time of day to control
for possible time-dependent factors such as fatigue and nicotine level fluctuations.
In the “free-smoke” condition (presence of nicotine), the participants were allowed to
smoke at their usual rates contingent upon them displaying an 11 ppm or higher carbon
monoxide (CO) level prior to assessment. The literature suggests this CO level to be
indicative of a nicotine present condition (George, Vessicchio, et al., 2000; Hatsukami et
al., 1989). The nicotine abstinent condition began following smoking abstinence by the
participants (absence of nicotine condition), operationalized as a CO reading of 10 ppm
or less. The literature suggests that this level is sufficient for establishing an absence of
nicotine condition (George, Vessicchio, et al., 2000; Hatsukami et al., 1989; Roll,
Higgins, Steingard, & McGinley, 1998). Participants were asked to refrain from smoking
for 6 hours or more in order to obtain this CO level. Hatuskami et al. (1989) observed
nicotine abstinence effects 4 hours after last smoking with the most notable effects seen
following 6-hour abstinence. The literature also reports nicotine half-life to be about 2
hours (Thornton et al., 1996; Tidey, Higgins, Bickel, & Steingard, 1999), with CO
elimination generally 2 -3 times slower than nicotine (Jarvik et al., 2000). These findings
taken in unison suggest a 6rhour abstinent requirement is sufficient to establish a
nicotine abstinence condition. Length of abstinence to achieve a CO level of 10 ppm or
less for participants in this study ranged from 6 to 14 hours.
The principal investigator (PI) conducted all assessments.

At time of testing the PI

had 3+ years of testing experience, had received extensive cognitive (and pathology)
testing training, and was a certified rater on several industry sponsored clinical trials.
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Upon arrival for their testing visits, each participant submitted a CO sample. Following
verification of smoking presence/abstinence each subject began testing. Testing began
with the first 6 trials of the RAVLT followed by administration of the CPT-II. Following
completion of the CPT-II, the participant completed trial 7 and the recognition trial on the
RVLT. Participants were then retested s 1 week later in the appropriate alternate
nicotine condition (presence or absence).

Statistics
Data were analyzed using repeated measures ANOVAs with condition (freesmoke/nicotine abstinence) as the within subjects factor. The cutoff for significance was
p < .05, two-tailed.

Supplementary analyses were conducted to determine if age, sex,

education level, change in CO level between testing conditions, number of cigarettes
smoked per day, or level of nicotine dependence influenced the results. Continuous and
dichotomous variables were entered as covariates, and categorical variables were
analyzed using Spearman’s rho. Due to low-sample size, each covariate was entered
into the model separately. Also due to low sample size, and the need to remove outlier
scores on the C P T for one participant, race could not be included as a factor. All
analyses were performed using SPSS version 14 for Windows software. Statistical
procedures and outcomes were verified by the senior biostatistician for Dr. Flerbert
Meltzer’s group at Vanderbilt, and by the V P for Research at Centerstone who holds a
Ph.D. from Vanderbilt in Clinical and Quantitative Psychology.
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CHAPTER III

RESULTS

Descriptives
Thirteen subjects, four male and nine female, participated in the study. Mean age for
participants was 37.5 years (SD=10.6) and mean education was 15.2 years (SD+1.7).
10 of the participants were Caucasian, two African-American and one Hispanic.

Smoking
Mean nicotine dependence as determined by the FTND was “medium dependent”
and mean cigarettes per day was 18.4 (SD=6.4). All participants reported some daily
caffeine consumption with mean cup per day of 5.1 (SD=3.8). Correlation analysis
revealed a strong correlation between FTND score and cig/day, r (11) = .90, p = .000;
FTND and CO level during the nicotine present condition, r (11) = .88, p = .000; and
between CO level during nicotine present condition and cig/day, r(1 3 ) = .77, p = .002.
This indicates that FTND score, CO level, and cig/day are all good measures of daily
nicotine intake and is consistent with the literature.

Change in R V LT scores
Means, standard deviations, t scores and p values for relevant RVLT subscales are
presented in Table 1. Paired samples t-tests, correlation and repeated measures
analysis of variance were conducted on variables RVLTV, RVLTTT, RVLTVII,
RVLTCORREC, and RVLTRECDISCR. As stated above, additional analyses on
potential covariates were conducted on all variables.
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Table 1: Mean ± SD and t-scores (p) for RVLT nicotine conditions
Nicotine Condition
RVLT sub-measure

present

absent

t score (p)

RVLTV3

13.7 ± 1.2

13.6 ± 1 . 5

.25 (.811

RVLTTTa

62.2 ± 6 . 9

57.6 ± 7 . 1

2.1 (.061

RVLTVII0

12.8 + 2.1

12.2 ± 1.8

.83 (.431

RVLTCO RREC3

13.9 + 1.0

14.2 ± 1.2

.90 (.391

RVLTRECDISCR (%13

96.6 ± 3.0

97.4 ± 4.0

.75 (.471

Note. RVLT = Rev Auditory Verbal Learning Test; RVLI I I = RVLT total
for trials 1 - 5 ; RVLTVII = RVLT trial 7 (delayed recall); RVLTCORREC = RVLT correct
recognitions: RVLTRECDISCR = RVLT recognition discrimination %.
an = 1 3 . b n = 11 due to administration error.
The repeated-measures ANO VA revealed no statistically significant differences
between nicotine conditions on any of the RVLT measures; however, a trend toward
significance was found for variable RVL I I I , F(1,12) = 4.41, p = .057. Subsequent
analyses on potential covariates revealed a significant effect of nicotine condition on
RVLTTT when controlling for sex, F (1 ,1 1) = 4.96, p = .05, and when controlling for
cig/day, F (1 ,11) = 7.41, p = .020. Nicotine had a greater effect on females scores than
on males. Nicotine also had a greater effect in those who smoked more cig/day with 15+
cig/day smoked showing clearly better scores in the free smoke condition (see Figure 1).
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Figure 1: RVLTT Score Change
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An examination of trend lines from the nicotine presence to the nicotine abstinence
condition revealed a worsening of score during the nicotine abstinence condition for
variables RVLTV, RVLTTT and RVLTVII, and an improvement in scores for the
RVLTCO REC and RVLTRECDISCR. As mentioned above, the former variables are
taken to represent memory retrieval while the latter represent memory storage. These
differing trend lines are consistent with the literature that shows nicotine to have different
effects depending upon the construct.

Change in C P T raw scores
Means, standard deviations, t scores and p values for the CPT subscales raw
scores are presented in Table 2. Paired samples t-tests, correlation and repeated
measures analysis of variance were conducted on variables all 13 subscales. As with
the RVLT analysis, additional analyses on potential covariates were conducted on all
variables.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

48

Table 2: Mean ± SD and t-scores (p) for CPT nicotine conditions
Nicotine Condition
CPT submeasure3

present

absent

t score (p)

CPTB

.892 ± 2.220

.250 ± .243

1.08 (.30)

CPTOmiss

.750 ± 1.060

.750 ± 1.765

0 (1 )

CPTCommiss

9.920 ± 3.630

11.580 ± 5 .2 3 0

2.13 (.06)

C PTHITRT

366.250 ± 43.653

366.717 ± 3 1 .8 7 3

.11 (.92)

CPTHITRTSE

4.792 ± 1.221

5.208 ± .908

1.75 (.11)

CPTVAR

4.850 ± 1.767

5.942 ± 1.783

1.89 (.09)

CPTd’

.750 ± .261

.808 ± .527

.63 (.55)

CPTHITRTISI

.068 ± .032

.071 ± .033

.38 (.71)

CPTHITSEISI

.029 ± .053

.071 ± .095

1.32 (.21)

CPTPERS

0±0

0±0

-

CPTHITRTBC

0 ± .013

.006 ± .025

.70 (.50)

CPTHITSEBC

-.023 ± .057

0 ± .051

1.20 (.26)

CPTOI

1.540 ± 2 .7 8 6

2.478 ± 3.068

.95 (.36)

Note. CPT = Continuous Performance test 1'est; CPTB = CPT beta; CPTOmiss
omissions; CPTCommiss = CPY commissions; C P TH ITR T = C P T hit reaction time;
C PTHTRTSE = CPTH ITR T standard error; CPTVAR = CPT variability of standard error;
CPTd’ = CPT attentiveness; CPTHITRTISI = C P TH ITR T inter-stimulus intervals;
CPTHITSEISI = CPTHITRTISI standard error; C PTPER S = CPT perseverations;
CPTHITRTBC = C P TH ITR T block change; CPTHITSEBC = CPTHITRTB C standard
error; CPTOI = CPT overall index.
- could not be calculated due to S E of 0.
an = 12 for all analyses.
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The repeated-measures ANO VA revealed no statistically significant differences
between nicotine conditions on any of the CPT measures. However several CPT
measures showed a trend toward significance and warranted subsequent analysis while
controlling for covariates. F scores for the CPT measures primary and covariate
analyses are presented in Table 3. As shown in the table there was a statistically
significant difference on the CPTOI and CPTHITRTB C between nicotine conditions while
controlling for age. The CPTOI is a general indicator of performance on the C P T with
scores of 8 or lower indicative of good overall performance. The CPTHITRTBC
measures the slope of change in reaction time across the six time blocks. Higher tscores indicate a slowing of reaction time as the test progressed and represents a loss
of vigilance. As table 2 shows, mean scores rose on both measures during the nicotine
absent condition. On closer inspection, 2 participants under the age of 26 both had an
increase from 0 (nicotine present) to 5.63 (nicotine absent) on the CPTOI while other
age related changes were negligible. It is doubtful that any actual significance can be
taken from the differences on the CPTOI subscale.

Examination of the CPTHITRTBC

scores revealed that 4 out of 5 individuals aged 30 or less performed better during the
nicotine present condition while only 2 of 7 individuals over the age of 38 showed the
same effect. This indicates that smoking prevented a slowing of reaction time as the test
progressed in younger participants.
An examination of trend lines from the nicotine presence to the nicotine abstinence
condition revealed a worsening of score during the nicotine abstinence condition for all
CPT variables except for CPTOmiss which showed no change and CPTPers where no
scores were recorded under either nicotine condition. This worsening of scores across
all subscales indicates slower reaction times, inconsistent responding, more errors,
inattention, impulsiveness, and poorer vigilance under the nicotine absence condition.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Although the size of the effect was smaller, the direction is consistent with literature
showing nicotine to improve attention and vigilance.

Table 3: Repeated-measure ANO VA and covariate analysis for CPT raw scores
CPT submeasure3

Primary analysis

Covariate analysis

CPTCommiss

F (1 ,1 1) = 4.55, p = 056

-

C PTH ITR TSE

F(1,11) = 3.07, p = . 107

F (1 ,10) = 3.81, p =.08b

CPTVAR

F(1,11) = 3.56, p = 086

-

CPTHITRTISI

NS

F(1,10) = 4.28, p = 065°

CPTHITRTBC

NS

F( 1,10) 4.96, p = 05 b*

CPTOI

NS

F( 1,10) 6.39, p = 03 b*

Note. C P T = Continuous Performance test Test; CPTB = CPT beta; CPTCommiss
= CPT commissions; CPTHITRTSE = C P T hit reaction time standard error; CPTVAR
C P T variability of standard error; C PTHITRTISI = CPTH ITR T inter-stimulus intervals;
CPTHITRTB C = CPTH ITR T block change; CPTOI = C P T overall index. NS = not
significant or near significant. - = covariate did not significantly affect the p value.
an = 12 for all analyses.
bage as covariate.
Education as covariate.
* p < .05

Change in indicators of inattention, impulsivity, and vigilance
As mentioned previously CPT subscales can be grouped to form indicators of
inattention (CPTOmiss, CPTCommiss, CPTHITRT, CPTHITRTSE, CPTVAR, C P Td’,
CPTPERS, CPTHITRTBC, CPTHITSEBC, CPTHITRTISI, and CPTHITSEISI)
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impulsivity (CPTCommiss, CPTHITRT, and CPTPER S) and vigilance (CPTHITRTBC
and CPTHITSEBC).

The age and sex-corrected t scores for each relevant subscale

were added together to represent their respective indicators, and analyses were
conducted to compare these indicators across nicotine condition. Covariate analysis
was performed if indicated.
The repeated-measures ANO VA revealed no statistically significant differences
between nicotine conditions on any of the CPT indicators. There was a near significant
difference for the impulsivity indicator F (1 ,12) = 3.33, p = .095. As was the case with the
C P T subscale raw scores, Figure 2 illustrates poorer performance in the nicotine
abstinence condition for all three indicators.

Figure 2: CPT Factor Changes
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CHAPTER IV

DISCUSSIO N

This study examined the effects of acute nicotine abstinence on measures of
attention and verbal memory. The literature has shown deficits in these areas to
correlate with poor social functioning in schizophrenic patients. Further, the
overwhelming majority of evidence has shown nicotine to mitigate deficits in these areas
in diagnosed patients, but this has not been as reliably demonstrated in non-diagnosed
populations. The main findings of this study were: 1) consistent with previous findings
the FTND scores correlated with number of cigarettes smoked per day and carbon
monoxide level at the nicotine present condition; 2) a significant effect of nicotine
condition on RVLTTT when controlling for sex, F( 1,11) = 4.96, p = .05, and when
controlling for cig/day, F( 1,11) = 7.41, p = .020; 3) An examination of trend lines from the
nicotine presence to the nicotine abstinence condition revealed a worsening of score
during the nicotine abstinence condition for variables RVLTV, RVLTTT and RVLTVII
(memory retrieval), and an improvement in scores for the RVLTCO REC and
RVLTRECDISCR (memory storage); 4) a statistically significant difference on the CPTOI
and CPTHITRTBC between nicotine conditions while controlling for age, F( 1,10) 6.39, p
=.03 and F(1,10) 4.96, p =.05 respectively; 5) An examination of trend lines from the
nicotine presence to the nicotine abstinence condition revealed a worsening of score
during the nicotine abstinence condition for all CPT variables except for CPTOmiss
which showed no change and CPTPers where no scores were recorded under either
nicotine condition. Poorer performance in the nicotine abstinence condition was also
observed for all three CPT indicators - inattentiveness, impulsivity and vigilance.
Verifying smoking or smoking abstinence via CO level and administering the FTND
and documenting cigarettes smoked per day (cig/day) to determine level of addiction is
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common place in nicotine research with humans; however, only a few of these studies
have reported information about the relationship between these variables. Payne et al.
(1994) reported positive correlations between FTND and CO level, Jacobsen et al.
(2005) between FTND and cig/day, and Steinberg et al. (2005) reported FTND was
positively correlated to both CO level and cig/day.

The current study bolstered these

studies by finding very strong correlations between these three variables.
The current study revealed that nicotine had a significantly greater effect on females
RVLT total scores (RVLTTT) than on the same scores in males. There is some literature
to support that nicotine effects are different based on sex. Trimmel and Wittberger
(2004) found nicotine had a larger effect in females on tests of attention and vigilance.
Razani et al. (2004) reported sex was a significant covariate for nicotine effects on
W C ST categories and % concept-level responses.

However, Jacobsen et al. (2005)

reported no sex differences in the effect of nicotine on the CPT.

While no conclusions

can be drawn from the current findings, sex differences in nicotine effects on constructs
would not be surprising due to sex differences in nicotine metabolism (Le Houzec,
2003).
The current study also found that nicotine exerted more of an effect on RVLTTT
scores in heavy smokers than in light smokers. This is not a surprising finding in that
heavy smokers more closely resemble, in terms of number of cigarettes smoked,
smoking topography, and possible shared neurobiological abnormalities, diagnosed
populations where nicotine effects are more easily seen. This would also be expected
given the literature that supports low affinity a-7 receptor involvement which requires a
higher dose of nicotine to depolarize. Although due to delivery mechanism exact dose is
difficult to determine, Le Houzec (2003) does report that nicotine yield per cigarette is
about 1.0mg independent of FTC yield reports. So the greater effect of nicotine in heavy
smokers is consistent with controlled dose studies such as Poltavski and Petros (2005)
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that show dose-dependent effects on verbal recall. Further, if heavy smokers are
smoking to mitigate neurobiological differences while light smokers smoke for other
reasons related to reinforcement, anxiety reduction, etc., Poltavski and Petros (2006)
assertion is that we would expect to see less improvements as a result of nicotine in
those whose performance is already optimized. This subset of non-diagnosed smokers
who may have a genetic and neurobiological make up similar to diagnosed populations
may add to the variability seen in smoking behaviors (Kumari and Postma, 2005), which
adds to the difficulty in interpreting the results of nicotine research.
The trend lines showing different effects of nicotine on storage and encoding
memory are of interest, and consistent with our literature that pointed to a lack of
consistent findings of an effect of nicotine on memory.

Consistent, in part, with the

trend reported in the current study, Mangan (1983) showed that nicotine improved long
term memory but had no effect on short term memory on a word list task. Warburton et
al. (1992) found an effect of nicotine in smokers on both immediate and delayed recall.
However, upon closer inspection of the data reported, the effect was far from universal
as 6 out of 14 and 6 out of 13 participants either failed to show improvement or showed
a decrement in performance on the immediate and delayed recall tasks, respectively.
Still other studies showed no effect of nicotine on verbal memory in smokers (Harris et
al., 2004; Smith et al., 2006). Newhouse, Potter, and Singh’s (2004) claim that nicotine
effects on memory, acquisition, encoding, storage, and retrieval in normal smokers is a
result of nicotine’s attentional effects on the front end appears to be in question.

Levin,

et al. (2006) assert that nicotine effects on memory are less frequently seen in humans,
and are more clearly seen in rat studies (e.g. Rezvani and Levin, 2001; Levin, 1992).
The most consistent finding in human research in this area is that nicotine has a positive
effect on spatial memory in diagnosed patients and a detrimental effect on spatial
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memory in non-diagnosed. Park, et al. (2000) appear well justified in using VSW M
impairments as a potential marker for schizophrenia.
In the current study a significant effect of nicotine was found on the C P T overall
index (CPTO I) and CPT hit rate block change (CPTHITRTBC) when controlling for age.
Upon closer inspection it appeared that the effect was on preventing a slowing of
reaction time in younger participants.

This result at least partially confirms previous

findings. O f more importance, I believe, is the finding of no statistical difference in this
population but trend lines all in the predicted direction, i.e. nicotine improving vigilance,
inattention, and impulsivity.
Common criticisms of studies investigating the acute effects of nicotine are small
sample and effect sizes. Kleykamp, et al. (2005) suggest that modest effect sizes on
cognitive measures coupled with small samples sizes in studies involving never smokers
may result in an increased probability of type II error. However the authors also suggest
that these small effect sizes may be telling us that cognitive effects may not be a
significant factor in the initiation of smoking by healthy adults. However effect and
sample size do not appear to be as important factors when looking at nicotine effects in
smokers and individuals with diagnoses related to cognitive impairment and people
demonstrating pre-diagnostic or mild cognitive impairment (MCI). Harte and Kanarek
(2004) state that we most consistently see increased performance on the CPT in
deprived smokers. Bekker, et al. (2005) suggests using only smokers when asking
questions about smokers, because nicotine effects in non-smokers may not generalize
due to neurobiological abnormalities in smokers. Newhouse, et al. (2004) also suggest
neurobiological differences between non-smokers and smokers.
The literature also points to differential effects of nicotine between non-diagnosed
and clinical populations. Differential effects of nicotine on cognition in normal and
cognitively impaired populations are of particular interest since these may point to
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reasons for the differential prevalence of smoking between these two populations.

Both

Poltavski and Petros (2006) and Newhouse, et al. (2004) assert that nicotine optimizes
performance, and when performance is already optimized, results in a decrement in
performance. Poltavski and Petros (2006) make the claim, that I’m making here, that it
is reasonable to expect less improvement or even deficits in participants whose
performance is already optimized. The way to look for improvement in those already
optimized individuals is to increase task difficulty (Newhouse et al., 2004).

Strengths and weaknesses o f current study
Using standardized and psychometrically sound assessment instruments that
measured clinically meaningful constructs was a significant strength of this study. The
constructs measured were not chosen because it was believed that these would most
easily show nicotine effects, nor were they chosen because of the large literature
surrounding them: they were chosen because they were correlated with impaired
behaviors in schizophrenic patients that severely impact their ability to function.
Standardized administration of the instruments by a single trained rater added to the
strength of the instruments used.
Another strength of the study was the study design. The study employed a
counterbalanced (crossover) repeated-measures design, where participants were
randomly assigned to which nicotine condition they would participate in first. This design
controlled for order effects related to nicotine condition (abstinence or free-smoke),
possible effects of time, and any practice effects related to the dependent variables. In a
small sample size study sound design is even more important.
Choosing smoking as the delivery mechanism can be viewed as a strength and a
weakness of the study. It is considered a weakness due to the inability to control the
exact dose of nicotine delivered and therefore being unable to ascertain any dose
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dependent effects. However, using controlled delivery mechanisms such as patch, gum,
nasal spray, subcutaneous or i.v. may not deliver the dose rapidly enough to depolarize
the a-7 receptors thought to be responsible for the effects of nicotine on cognition
without first desensitizing these same receptors.

Further Bekker, et al. (2005) state,

while discussing reasons for mixed results on dose-dependent effects, that plasma
concentrations in transdermal admin varies just as greatly as in smokers, inter-individual
differences, body weight, gender, absorption rate all contribute to error variance and
may mask effects.

Likewise Le Houzec (2003) reports variation in absorption rate when

nicotine is delivered via gum.

The inter-individual differences mentioned by Bekker, et

al. (2005) exist regardless of delivery mechanism. Also, a presumed source of variance,
the type or brand of cigarette smoked, Le Houzec (2003) reports not to be as much of a
source of variation as frequently referenced. He reported that regardless of Federal
Trade Commission (FTC) nicotine yield estimates for cigarettes, that the average
smoker yields 1.0 mg (range .97 - 1.39) from a single cigarette.

This does not, of

course, mitigate differences in smoking topography observed between most notably
diagnosed and non-diagnosed populations.
As a strength, smoking ad libitum allows us to see if nicotine as self-administered
impacts vigilance and verbal memory. And the immediacy of delivery allows us to
confidently assume that the low-affinity a -7 receptors were activated.
One obvious weakness, and one that is pervasive in this line of inquiry, is the low
sample size. Even though pre-study power analysis suggested that a sample size as
low as 9 may be large enough to detect an effect, a larger sample size would allow more
confident comments to be made about this study.

Levin et al. (1998) reported effects of

nicotine on the CPT in normals with a sample size of 11.

However other studies that

have reported nicotine effects on the C P T in normal smokers have had larger samples,
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and those studies with small samples reporting an effect of nicotine on the C P T have
been with diagnosed populations (White and Levin, 1999; Levin, Wilson, et al., 1996).
Not only does this study highlight the importance of effect sizes, but it points to a need to
pay attention to effect size differences between populations. Not only may this be
instructive for determining different etiologies of smoking between populations, but it
informs researchers to use effect sizes relevant to the population under investigation
when conducting pre-study sample size estimates.
Another problem related to the small sample size is the need to conduct multiple
ANO VA’s and covariate analyses. Conducting multiple ANO VA’s increases the
probability of making a Type 1 error, which as it turned out, wasn’t a problem in this
study. This problem was made a bit less threatening by utilizing the three factors on the
CPT (impulsivity, inattentiveness, and vigilance) which were derived from multiple
subscales. Also, having t-scores that accounted for age and sex helped. With the
RVLT, the RVLT total score was derived from 5 separate trials which helped decrease
the likelihood of Type 1 error; however it was still a concern on the other RVLT scores.

Summary and future direction
Admittedly drawing conclusions from a low sample study with few statistically
significant findings is a perilous task.

But the direction of the effect on attention is

consistent with the literature as is the mixed results found on the memory task. A less
robust finding in a non-diagnosed population than is typically found in diagnosed
populations is suggestive of different reasons for smoking between the populations.
Population, effect size, assessment tool, and smoking status are all variables that garner
much attention when conducting research in this area.
When considering future research, low sample size is a pervasive problem in this line
of research for a reason; it is hard for smokers to stop for any given time. Of course this
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is not surprising given the research showing how addictive cigarette smoking is. Future
studies aimed at assessing acute abstinence in smokers need to take control of this
factor and pair their research to smoking cessation programs or employ successful
smoking cessation strategies. In the current study the PI offered rudimentary advice
(drink water, chew gum, exercise, avoid caffeine., etc) to participants to help abstain
from smoking but more is warranted. Tidey, et al. (1999) and Roll, et al. (1998)
demonstrated that contingency management approaches to smoking cessation can be
as effective in persons diagnosed with schizophrenia as it is in non-diagnosed
populations. Sacco, et al. (2005) reported using 20:1 ratio of contingent reinforcement to
achieve 90% over night abstinence in both schizophrenic and control smokers.
Ziedonis, Wiliams, and Smelson (2003) have also reported success in conducting
smoking cessation groups in diagnosed populations.
Finally, future studies should be able to better isolate individual differences that may
relate to nicotine effects. Pre-study testing to determine low attention and mildly
cognitively impaired groups, as well as those with auditory inhibition abnormalities and
visuospatial deficits would help determine how these factors impact nicotine effects. W e
are more confident about genetic markers that may indicate a -7 deficits that may be at
the core of nicotine’s affect on attention and memory. Cheek swab genetic samples and
subsequent analyses are widely available and affordable, making them easier to include
in research protocols.
As existing methodologies undergo continued refinement, and neuroimaging and
pharmacological technologies improve, so will our ability to more confidently draw
conclusions about the relationship between smoking, receptor deficits, psychological
pathology, and social functioning.
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